Terms: = Breast cancer AND EBF1, COE1, 1879, ENSG00000164330, Q9UH73, OLF1, O/E-1, EBF AND Treatment
18 results:
1. Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality.
Parsons MW; Rock C; Chipman JJ; Shah HR; Hu B; Stephens DM; Tao R; Tward JD; Gaffney DK
Cancer Med; 2023 Feb; 12(3):2624-2636. PubMed ID: 36812123
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
[TBL] [Abstract] [Full Text] [Related]
3. ebf1 promotes triple-negative breast cancer progression by surveillance of the HIF1α pathway.
Qiu Z; Guo W; Dong B; Wang Y; Deng P; Wang C; Liu J; Zhang Q; Grosschedl R; Yu Z; Deng J; Wu Y
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2119518119. PubMed ID: 35867755
[TBL] [Abstract] [Full Text] [Related]
4. ebf1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA.
Shuang O; Zhou J; Cai Z; Liao L; Wang Y; Wang W; Xu M
J Orthop Surg Res; 2022 Jun; 17(1):332. PubMed ID: 35761386
[TBL] [Abstract] [Full Text] [Related]
5. Delay in the diagnosis and treatment of breast cancer in Vietnam.
Nguyen SM; Nguyen QT; Nguyen LM; Pham AT; Luu HN; Tran HTT; Tran TV; Shu XO
Cancer Med; 2021 Nov; 10(21):7683-7691. PubMed ID: 34664428
[TBL] [Abstract] [Full Text] [Related]
6. Hormone replacement therapy and cancer survival: a longitudinal cohort study: protocol paper.
Ranger TA; Burchardt J; Clift AK; Mei WX; Coupland C; Tan PS; Dixon S; Cardwell CR; Hippisley-Cox J
BMJ Open; 2021 Aug; 11(8):e046701. PubMed ID: 34341043
[TBL] [Abstract] [Full Text] [Related]
7. Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system.
Eaglehouse YL; Georg MW; Shriver CD; Zhu K
Breast Cancer Res Treat; 2019 Nov; 178(2):441-450. PubMed ID: 31414244
[TBL] [Abstract] [Full Text] [Related]
8. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results.
Burt LM; Ying J; Poppe MM; Suneja G; Gaffney DK
Breast; 2017 Oct; 35():122-129. PubMed ID: 28719811
[TBL] [Abstract] [Full Text] [Related]
9. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
[TBL] [Abstract] [Full Text] [Related]
10. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract] [Full Text] [Related]
11. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
Tward JD; Wendland MM; Shrieve DC; Szabo A; Gaffney DK
Cancer; 2006 Jul; 107(1):108-15. PubMed ID: 16708354
[TBL] [Abstract] [Full Text] [Related]
12. Thyroid cancer and multiple primary tumors in the SEER cancer registries.
Ronckers CM; McCarron P; Ron E
Int J Cancer; 2005 Nov; 117(2):281-8. PubMed ID: 15880372
[TBL] [Abstract] [Full Text] [Related]
13. Estimating the cumulative risk of a false-positive test in a repeated screening program.
Xu JL; Fagerstrom RM; Prorok PC; Kramer BS
Biometrics; 2004 Sep; 60(3):651-60. PubMed ID: 15339287
[TBL] [Abstract] [Full Text] [Related]
14. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases.
Chang EL; Hassenbusch SJ; Shiu AS; Lang FF; Allen PK; Sawaya R; Maor MH
Neurosurgery; 2003 Aug; 53(2):272-80; discussion 280-1. PubMed ID: 12925241
[TBL] [Abstract] [Full Text] [Related]
15. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.
Dores GM; Metayer C; Curtis RE; Lynch CF; Clarke EA; Glimelius B; Storm H; Pukkala E; van Leeuwen FE; Holowaty EJ; Andersson M; Wiklund T; Joensuu T; van't Veer MB; Stovall M; Gospodarowicz M; Travis LB
J Clin Oncol; 2002 Aug; 20(16):3484-94. PubMed ID: 12177110
[TBL] [Abstract] [Full Text] [Related]
16. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract] [Full Text] [Related]
17. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease.
Henry-Amar M
Ann Oncol; 1992 Sep; 3 Suppl 4():117-28. PubMed ID: 1450072
[TBL] [Abstract] [Full Text] [Related]
18. Second primary cancer after treatment of invasive carcinoma of the uterine cervix, compared with those arising after treatment for in situ carcinomas. An effect of irradiation? A cancer registry study.
Pettersson F; Ryberg M; Malker B
Acta Obstet Gynecol Scand; 1990; 69(2):161-74. PubMed ID: 2386020
[TBL] [Abstract] [Full Text] [Related]
